Overview

Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)

Status:
Not yet recruiting

Trial end date:
2022-11-01

Target enrollment:

Participant gender:

Summary

This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib in patients hospitalized with moderate-to-severe COVID-19 (based on World Health Organization [WHO] Ordinal Scale for Clinical Improvement). Both famotidine and celecoxib separately demonstrate clinical activity in mitigating COVID-19 disease symptoms or severity, and appear to have separate and complementary mechanisms of action.

Phase:

Phase 2

Details

Lead Sponsor:

Leidos Life Sciences

Collaborator:

United States Department of Defense

Treatments:

Celecoxib
Famotidine